{
    "clinical_study": {
        "@rank": "33364", 
        "arm_group": [
            {
                "arm_group_label": "L/VL APOE e3/e4 carrier", 
                "arm_group_type": "Other", 
                "description": "long and very long poly - T variants of TOMM40 and APOE e3/e4 carrier"
            }, 
            {
                "arm_group_label": "L/S APOE e3/e4 carrier", 
                "arm_group_type": "Other", 
                "description": "long and short poly - T variants of TOMM40 and APOE e3/e4 carrier"
            }, 
            {
                "arm_group_label": "S/VL APOE e3/e3 carrier", 
                "arm_group_type": "Other", 
                "description": "short and Very long poly - T variants of TOMM40 and APOE e3/e3 carrier"
            }, 
            {
                "arm_group_label": "VL/VL  APOE e3/e3 carrier", 
                "arm_group_type": "Other", 
                "description": "Very long poly - T variants of TOMM40 and APOE e3/e3 carrier"
            }, 
            {
                "arm_group_label": "S/S APOE e3/e3 carrier", 
                "arm_group_type": "Other", 
                "description": "short poly - T variants of TOMM40 and APOE e3/e3 carrier"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators' goal is to determine if certain tests of memory and attention, performed\n      while sleepiness is induced by a single dose of lorazepam, can predict whether or not an\n      individual is at risk for developing Alzheimer's disease."
        }, 
        "brief_title": "The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease (AD)", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  MMSE score of 28-30\n\n          -  Hamilton Depression Rating Scale score of less than 10\n\n          -  participants in longitudinal study of aging and have a TOMM40 genotype of S/S, VL/VL,\n             S/VL, L/S or L/VL.\n\n        Exclusion criteria:\n\n          -  Alzheimer's Disease or Mild Cognitive Impairment\n\n          -  any significant medical, psychiatric, and neurological illnesses, e.g., impaired\n             liver or kidney function, prior stroke, traumatic brain injury, memory impairment,\n             cognitive impairment, parkinsonism, a lifetime history of schizophrenia, bipolar\n             disorder, a psychoactive substance use disorder, or current major depression.\n\n          -  known allergy to benzodiazepines\n\n          -  current use (within the previous four weeks) of benzodiazepines or other medications\n             known to interact with lorazepam, current use of sedating antihistamines, or current\n             use of stimulant medications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01780519", 
            "org_study_id": "12-006469"
        }, 
        "intervention": {
            "arm_group_label": [
                "L/VL APOE e3/e4 carrier", 
                "L/S APOE e3/e4 carrier", 
                "S/VL APOE e3/e3 carrier", 
                "VL/VL  APOE e3/e3 carrier", 
                "S/S APOE e3/e3 carrier"
            ], 
            "description": "single dose of 1 mg lorazepam", 
            "intervention_name": "lorazepam", 
            "intervention_type": "Drug", 
            "other_name": "Ativan"
        }, 
        "intervention_browse": {
            "mesh_term": "Lorazepam"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Alzheimer's disease (AD)", 
        "lastchanged_date": "January 30, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Scottsdale", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85259"
                }, 
                "name": "Mayo Clinic"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms", 
        "overall_contact": {
            "email": "Light.Jan@mayo.edu", 
            "last_name": "Jan A Light, LPN", 
            "phone": "(480) 301-8788"
        }, 
        "overall_contact_backup": {
            "email": "henslin.bruce@mayo.edu", 
            "last_name": "Bruce Henslin", 
            "phone": "480-301-8549"
        }, 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Cynthia Stonnington, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The AVLT (Rey Auditory Verbal Learning Test),  a verbal memory test, is a 15-word list presented over 5 learning trials. After each presentation, the subject immediately repeats as many words as possible, then does so again after 30 minutes, which is the \"long-term memory\" score. \"Percent recall\" is long-term memory divided by learning trial 5. The \"learning over trials\" score reflects the increment in words repeated over the 5 successive learning trials. Six equivalent alternate forms of the AVLT will be randomly assigned to each subject.", 
                "measure": "AVLT Long term memory score", 
                "safety_issue": "No", 
                "time_frame": "baseline to 5 hours"
            }, 
            {
                "description": "The GMLT assesses visuospatial working memory, error monitoring, information processing speed, and short-term delayed recall for a complex hidden maze. Subjects are familiarized with the task during two untimed practice tests, and once the tester is confident that the subject understands the rules and can move easily around the grid, the timed test is administered. In each of the 5 successive trials of the GMLT exam, the subject is asked to learn to navigate his or her way around a 28-step maze that is hidden beneath a 10 x 10 grid of squares on the computer touch screen.  For each trial, the time to completion, number of correct moves, number of wrong moves, and the number of perseverative errors are recorded.", 
                "measure": "Groton Maze Learning Test (GMLT) score", 
                "safety_issue": "No", 
                "time_frame": "baseline to 5 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01780519"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Cynthia M. Stonnington, M.D.", 
            "investigator_title": "PI", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}